Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin

A.M. Turner[1], L. Li[1], I.R. Monk[1], J.Y.H. Lee[1,2], D.J. Ingle[1], S. Duchene[1], N.L. Sherry[1,3,4], T.P.

Stinear[1], J.C. Kwong[1,4], C.L. Gorrie[1,3]*, B.P. Howden[1,3,4]*† and G.P. Carter[1]*†

[1]Department of Microbiology & Immunology, The Peter Doherty Institute for Infection and

Immunity, The University of Melbourne, Melbourne, VIC, Australia

[2]Department of Infectious Diseases, Monash Health, Clayton, VIC, Australia

[3]Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and

Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and

Immunity, Melbourne, VIC, Australia

[4]Department of Infectious Diseases, Austin Health, Melbourne, VIC, Australia

*These authors supervised this work equally.

†**Corresponding authors:** glen.carter@unimelb.edu.au, bhowden@unimelb.edu.au

Abstract

Bacterial pathogens such as vancomycin-resistant *Enterococcus faecium* (VREfm) that are

resistant to almost all antibiotics are among the top global threats to human health.

Daptomycin is a new last-resort antibiotic for VREfm infections with a novel mode-of-action,

but for which resistance has surprisingly and alarmingly been widely reported. The causes of

such a rapid emergence of resistance to this novel antibiotic have been unclear. Here we show

that the use of rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic

encephalopathy in liver disease patients, is causing resistance to this last-resort antibiotic in

VREfm. We show that mutations within the bacterial RNA polymerase complex confer cross-

resistance to both rifaximin and daptomycin. Furthermore, VREfm with these mutations are

spread globally across at least 5 continents and 20 countries, making this a major yet

previously unrecognised mechanism of resistance. Until now, rifaximin has been considered

'low-risk' for development of antibiotic resistance. Our study shows this is not the case and

that widespread rifaximin use may be compromising the clinical efficacy of daptomycin, one

of the major last-resort interventions for multidrug resistant pathogens. These findings

demonstrate that unanticipated antibiotic cross-resistance may potentially undermine global

strategies designed to preserve the clinical use of last-resort antibiotics.

Main

Antimicrobial resistance (AMR) is one of the greatest public health threats that humanity

currently faces, with 1.27 million deaths being directly attributable to bacterial AMR in 2019[1].

The magnitude of this threat is therefore similar to that of malaria (558,000 global deaths in

2019)[2], HIV (690,000 deaths in 2019)[3], and diabetes mellitus (1.5 million deaths in 2019)[4].

Infectious caused by multidrug (MDR) and extensively drug resistant (XDR) pathogens are of

particular clinical concern since they are associated with frequent treatment failure and high-

rates of morbidity and mortality. The preservation of last-resort antibiotics that can be used

to treat these formidable pathogens is of critical importance.

Enterococcus faecium is one such formidable pathogen. It is a commensal of the human

gastrointestinal tract that has emerged as a major nosocomial pathogen[5]. The intrinsic

antibiotic resistance of hospital-associated clones coupled with their ability to rapidly acquire

additional antibiotic resistance genes makes *E. faecium* infections increasingly difficult to

treat[6]. In particular, strains resistant to vancomycin, the first-line antibiotic for invasive

infections, have emerged and disseminated globally due to the acquisition of transferable *van*

resistance genes[7]. Consequently, *E. faecium*, which is one of the ESKAPE pathogens

(*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter*

baumannii, *Pseudomonas aeruginosa*, and *Enterobacter spp.*), has been recognised by the

World Health Organization (WHO) as a 'high priority' bacterial pathogen[8].

The lipopeptide daptomycin is a WHO designated 'last-resort' antibiotic that is used 'off-label'

to treat severe vancomycin-resistant *E. faecium* (VREfm) infections[9]. The increasing reports

of daptomycin-resistant VREfm are of great clinical concern. The specific risk factors for

acquiring a daptomycin-resistant VREfm strain are poorly understood, however, patients with

a daptomycin-resistant, bloodstream isolate are generally more likely to have been exposed

to daptomycin[10,11]. Daptomycin resistance in clinical strains is commonly associated with the

presence of specific mutations in the regulatory system LiaRS and cardiolipin synthase Cls[12–

14]. However, many daptomycin-resistant VREfm contain wild-type (WT) *liaRS* and *cls* alleles,

indicating other unknown molecular pathways are involved[13,15,16].

In Australia, high rates (15%) of daptomycin-resistant VREfm were recently reported[17], but

the data were not epidemiologically robust and genetic determinants leading to resistance

were not defined. Accordingly, we undertook a combined genomic and phenotypic analysis

to investigate the daptomycin resistance mechanisms in VREfm. Here we show that

daptomycin resistance can emerge *de novo* in VREfm following exposure to rifaximin, a

commonly prescribed antibiotic used prophylactically to prevent hepatic encephalopathy[18] in

liver disease patients. Further, we show that rifaximin-mediated daptomycin resistance is

linked with the presence of novel mutations (G482D, H486Y, and S491F) within the rifampicin-

resistance determining region (RRDR) of RpoB. Importantly, patients given rifaximin were

significantly more likely to harbour daptomycin-resistant VREfm (that also carried RpoB

mutations) than patients who did not receive rifaximin. Finally, we show that the identified

RpoB mutations arose within the VREfm population soon after rifaximin was first approved

for clinical use and have since become globally established, with three independent VREfm

lineages currently circulating within at least 20 countries. Our work has therefore uncovered

a major new mechanism of daptomycin resistance in VREfm and identified rifaximin, an

antibiotic considered to be low-risk for the emergence of bacterial resistance[19], as an

important driver of last-resort antibiotic resistance.

Results

Daptomycin resistance in Australian VREfm is polygenic and does not correlate with known

resistance determinants.

Daptomycin susceptibility testing was performed on VREfm isolated during two unbiased

state-wide 'snapshot' studies undertaken for month-long periods in 2015 (n=294) and 2018

(n=423) in Victoria, Australia. The proportion of isolates resistant to daptomycin was 16.6%

(n=49) in 2015 and 15.3% (n=65) in 2018. Given the unexpectedly high rate of resistance

observed, we expanded the study to include additional VREfm isolated in 2017 (n=108) and

2018 (n=173) as part of the 'Controlling Superbugs' flagship study[20,21], with 28.4% (n=80) of

these isolates being resistant to daptomycin. Overall, we observed 189 (18.9%) daptomycin-

resistant VREfm isolates, indicating a very high prevalence of daptomycin resistance in

Victoria, Australia.

To investigate the relationship between daptomycin-resistant and daptomycin-susceptible

VREfm, whole-genome comparisons were made for the 998 study isolates plus two additional

finished VREfm genomes (one daptomycin-susceptible and one daptomycin-resistant). A

maximum-likelihood phylogeny was inferred from an alignment of 6,574 core genome single

nucleotide polymorphisms (SNPs) (Supplementary Figure 1). *In silico* multi-locus sequence

typing identified 36 sequence types (STs) within the 1000 isolates; 30 of these STs included at

least one of the 189 daptomycin-resistant VREfm. Daptomycin resistance was interspersed

throughout the tree (i.e. mostly polyphyletic), with several distinct clades. The largest clade

(ST203) of daptomycin-resistant strains, accounted for 42.3% of resistant isolates (n=80 of

189) and consisted of a single clone predominant during our sampling timeframe (2015 to

2018), suggestive of an expanding daptomycin-resistant lineage. The other predominant STs

(ST80, ST796, ST1421, and ST1424) consisted of several groups of resistant isolates that did

not cluster based on tree structure. The presence of daptomycin-resistant isolates in distinct

genetic backgrounds suggested daptomycin resistance has arisen independently within this

VREfm population on multiple occasions.

Given the high prevalence of daptomycin resistance in Australian VREfm isolates, we sought

to determine the genetic determinants leading to resistance. Only seven daptomycin-

resistant isolates (3.7%) contained the dual LiaR W73C and LiaS T120A mutations. This finding

is of note since current literature suggests these mutations are the most important

mechanism of daptomycin resistance in VREfm[9,12,22]. In addition, no daptomycin-resistant

isolates contained the H215R or R218Q mutations in Cls or the Q75K mutation in the septum

site determining protein (DivIVA), which have all previously been linked with daptomycin

resistance in VREfm[23]. The mechanism of daptomycin resistance in the majority (n=182) of

our resistant study isolates was therefore left largely unexplained by previously characterised

mutations.

The S491F mutation in RpoB is a novel mediator of daptomycin resistance in VREfm.

To identify the mutations associated with daptomycin resistance in our study isolates, we

performed a genome-wide association study (GWAS) approach on the collection of 1,000

VREfm isolates with known daptomycin MIC (Figure 1A). To account for the clonal population

structure of the collection, we first removed non-homoplastic variants from the list of core

genome mutations to reduce the data set to variants that were acquired at least twice across

the phylogeny. We then applied a linear mixed model using a kinship matrix as a random

effect. After correcting for multiple testing, the analysis identified 142 mutations (in 73 genes)

significantly ($P < 1 \times 10^{-10}$) associated with daptomycin resistance (as a binary variable with a

breakpoint of 8 mg L^{-1}). The top five most significant mutations were (i) I274S in an

uncharacterised ABC efflux protein ($P = 7.44 \times 10^{-15}$), (ii) G71S in an uncharacterised permease

protein ($P = 7.77 \times 10^{-14}$), (iii) V288L in a mannitol dehydrogenase protein ($P = 6.08 \times 10^{-12}$), (iv)

S491F in RpoB, which is the RNA polymerase ß subunit ($P = 1.57 \times 10^{-13}$), and (v) T634K in RpoC,

which is the RNA polymerase ß' subunit ($P = 4.40 \times 10^{-11}$).

Deletion of the genes encoding the ABC efflux protein, permease protein, or mannitol

dehydrogenase protein had no impact on daptomycin susceptibility in a clinical daptomycin-

susceptible strain of VREfm from the ST796 genetic background. Similarly, introduction of the

T634K mutation within RpoC did not lead to increased levels of daptomycin resistance.

However, introduction of the S491F substitution within RpoB, resulted in a 4-fold increase in

daptomycin MIC, from 2 mg L^{-1} to 8 mg L^{-1}, and a daptomycin-resistant phenotype. Since

mutations within *rpoB* have previously been associated with daptomycin resistance in

Staphylococcus aureus[24,25]*,* we focused further experimental investigations on the RpoB

S491F mutation.

Based on amino acid alignment, the S491F mutation is located within the predicted RRDR of

E. faecium RpoB, which spans amino acids 467 to 493 (inclusive). The majority of study isolates

(n=829, 82.9%) contained a WT RRDR; however, 169 (16.9%) VREfm contained at least one

mutation within this region (Figure 1B), with the S491F mutation being the most common

(n=105). This was followed by H486Y (n=16), G482D (n=12), G482V (n=10), Q473L (n=6),

H486R (n=5), and other uncommon (n=3) mutations.

Different mutations within the RRDR of RpoB result in daptomycin resistance in VREfm.

Given the association of the S491F mutation in RpoB with daptomycin resistance, we

hypothesised that other mutations within RpoB may also alter daptomycin susceptibility

(Figure 1B). In keeping with this hypothesis, we observed a putative correlation between

strains carrying individual G482D (n=12) and H486Y (n=16) mutations in RpoB and daptomycin

resistance, with 10 daptomycin-resistant isolates containing G482D (83.3% resistant) and 13

containing H486Y (81.3% resistant). Clinical isolates containing the G482D, H486Y, or S491F

mutations were interspersed throughout the phylogenetic tree and identified in distinct STs,

highly suggestive of multiple independent acquisitions (Figure 1C). Ongoing expansion was

also observed for one dominant, daptomycin-resistant clone (ST203) containing the S491F

mutation throughout the isolate collection period (2015-2018).

The G482D and H486Y mutations were also located within the predicted RRDR region,

suggesting a potential correlation between rifamycin and daptomycin resistance. Therefore,

rifampicin susceptibility testing (with rifampicin being a marker of rifamycin resistance[26]) was

performed on all clinical VREfm containing a RpoB mutation within the predicted RRDR

(n=169). A randomly selected collection (n=169) of isolates containing a WT RpoB RRDR were

used as a control group in this analysis. Mutations located within the predicted RRDR

correlated with high-level rifampicin resistance (median MIC 256 mg L^{-1}), while control

isolates containing the WT region displayed a median MIC of 8 mg L^{-1} (Supplementary Figure

2). The correlation between rifampicin and daptomycin resistance in clinical strains containing

the G482D, H486Y, and S491F mutations, suggested a novel link between rifamycin and

daptomycin resistance in VREfm.

To confirm the G482D and H486Y mutations in RpoB also led to rifamycin and daptomycin

resistance we constructed isogenic mutants carrying these mutations in the same rifamycin-

susceptible, daptomycin-susceptible, clinical strain of VREfm (ST796), used to make the S491F

RpoB isogenic mutant above. Introduction of the G482D, H486Y, or S491F RpoB mutations

resulted in a 7-fold decrease in rifampicin susceptibility compared to the WT strain, leading

to high-level rifampicin resistance (>512 mg L^{-1}) (Figure 1D). To confirm the changes in

rifampicin susceptibility were due to the introduction of each specific mutation and not

unknown secondary mutations, we reverted each RpoB mutation to WT by restoration of the

chromosomal allele. Complementation to the WT *rpoB* allele in each of the G482D, H486Y, or

S491F mutants resulted in reversion of rifampicin MIC to the WT level (8 mg L^{-1}), indicating

the RpoB mutations were responsible for the heightened levels of rifampicin resistance

observed (Figure 1D). To then determine if the G482D and H486Y mutations could also cause

daptomycin resistance, daptomycin susceptibility testing was performed. Similar to the S491F

isogenic strain, introduction of the G482D or H486Y mutation resulted in a 4-fold increase in

daptomycin MIC, from 2 mg L^{-1} to 8 mg L^{-1}, and a daptomycin-resistant phenotype (Figure 1E).

Complementation with the WT *rpoB* allele onto the chromosome resulted in reversion of

daptomycin MIC to the WT level, indicating the G482D, H486Y, and S491F RpoB mutations

resulted in cross-resistance to rifamycins and daptomycin in VREfm.

Given the reported importance of *liaRS* mutations in daptomycin-resistant VREfm, we also

introduced the well-characterised LiaR W73C and LiaS T120A mutations into the same clinical

strain of VREfm (Figure 1D). No difference in rifampicin MIC was observed after introduction

of the *liaRS* mutations, compared to the WT strain, indicating the cross-resistance observed

with the G482D, H486Y, and S491F mutations is unique to these RpoB substitutions. However,

compared to the WT, introduction of the *liaRS* mutations decreased daptomycin susceptibility

2-fold, with a reversion to the WT daptomycin MIC after complementation with the WT *liaRS*

alleles. The introduction of the *liaRS* mutations had less of an impact on daptomycin

susceptibility than the G482D, H486Y, and S491F RpoB mutations and did not result in a

daptomycin-resistant phenotype (MIC $\geq$8 mg L^{-1}). When considered in conjunction with the

genomic epidemiology data associated with this study, where *liaRS* mutations were less

common than the *rpoB* mutations in daptomycin-resistant VREfm (n=7 versus n=141,

respectively), our data suggests that mutations within RpoB might represent a previously

uncharacterised, yet important mechanism of daptomycin resistance in VREfm.

The G482D, H486Y and S491F RpoB mutations are common in international VREfm strains.

To determine if the *rpoB* mutations associated with daptomycin resistance observed in

Australian VREfm were representative of other VREfm isolates globally, we performed a large-

scale analysis using publicly available VREfm sequence data from healthcare-associated

strains (n=4,476; n=3,476 international and n=1,000 Australian) (Figure 2A). Of the isolates

analysed, 630 (14.3%) carried an amino acid substitution in the RRDR of RpoB, occurring at 16

positions (Figure 2B). The S491F mutation was the most common, being present in 461

isolates, and accounting for 77.9% of the RpoB mutations observed. Isolates carrying this

mutation originated from 20 countries, and *in silico* MLST showed the mutations were spread

across 21 different STs, with ST203 (44.7%), ST80 (30.2%), and ST117 (11.5%) accounting for

the majority (86.4%) of isolates carrying this substitution. Importantly, five VREfm harbouring

the S491F mutation also contained the *cfr(B)* (n=4) or *poxtA* (n=1) genes that confer resistance

to linezolid, suggesting near pan-resistant strains of VREfm have already emerged.

The H486Y mutation was the second most common, and was identified in 73 isolates,

equivalent to 11.6% of strains with mutations within the RRDR of RpoB. These isolates were

collected from 10 countries and *in silico* MLST identified 22 STs, with the most common being

ST203 (23.2%), ST796 (21.9%), and ST80 (20.5%). The G482D mutation was the third most

common, being identified in 43 isolates, and accounting for 6.8% of strains carrying RpoB

mutations. It was present in nine distinct STs, although mostly commonly in ST796 (65.1%)

and ST1421 (11.6%), and was identified in isolates from seven countries. Collectively, these

data indicated the G482D, H486Y, and S491F mutations, which confer cross-resistance to

rifamycins and daptomycin, are not restricted to Australian VREfm but are globally prevalent

in healthcare-associated VREfm strains.

To determine whether the identified RpoB mutations were enriched within healthcare-

associated VREfm (established as clade A1), we interrogated publicly available genomic

sequences of VREfm from clade A2 (n=98), known for being animal-associated[27]. In keeping

with previous findings, the maximum-likelihood tree clustered isolates into two main clades:

one healthcare-associated and one associated with VREfm from animals. No mutations were

identified in the RpoB RRDR region of strains isolated from animals, with our analyses showing

that RRDR RpoB mutations were significantly (P<0.001; Fisher's exact test) associated with

healthcare-associated VREfm. This suggests the identified RpoB mutations are primarily

enriched within the healthcare setting (Supplementary Figure 3).

Phylodynamics indicate the S491F RpoB mutation emerged within the VREfm population

following the clinical approval of rifaximin.

Given the predominance of the S491F mutation in globally distributed VREfm populations, we

used evolutionary phylodynamic analyses to understand its emergence. Within our Australian

isolates, we observed the expansion of a dominant ST203 clone from 2015 to 2018 that

carried the S491F mutation (Figure 1C). Since this clone comprised VREfm carrying the *vanA*

resistance cluster or operon, we sequenced all "historical" *vanA*-VREfm from our public health

laboratory (n=229), which consisted of every *vanA*-VREfm isolate collected from 2003 to

2014, to increase temporal signal. We then contextualised all Australian isolates (n=1,229)

with the international (n=3,389) VREfm in a maximum-likelihood phylogeny inferred from an

alignment of 9,277 SNPs and used clustering with core-genome MLST (cgMLST) to identify

three clusters containing the RpoB S491F mutation (Figure 3A). The same ST203 clone (Cluster

1) formed the largest cluster (n=219 taxa), consisting of isolates from Australia and United

Kingdom. Cluster 2 (n=85 taxa) consisted of ST80 and ST78 isolates from Australia, Europe,

South America, the United Kingdom, and the United States of America while Cluster 3 (n=68

taxa) consisted of ST80 isolates from Australia, Europe, and the United Kingdom.

To model the evolutionary trajectories of these three VREfm clusters, we used core-genome

SNP diversity and year of isolation (Figure 3B). Bayesian phylodynamic analyses were

conducted using the core-genome SNP alignments for each cluster/lineage with a discrete

trait model and constant coalescent tree prior. We assessed for temporal signal within each

cluster using a root-to-tip regression (Supplementary Figure 4). The substitution rate (the

number of expected substitutions per site per year) was consistent with other estimates for

healthcare-associated VREfm, otherwise referred to as clade A1[27–30]. The median substitution

rate was similar for Cluster 1 and Cluster 2, at 9.7×10^{-7} [95% highest posterior density (HPD)

$6.88\times10^{-7} – 1.24\times10^{-6}$] and 1.25×10^{-6} (95% HPD $7.68\times10^{-7} – 1.74\times10^{-6}$) respectively, but slightly

faster for Cluster 3 at 3.86×10^{-6} (95% HPD $2.23\times10^{-6} – 5.69\times10^{-6}$). The year of emergence for

the most recent common ancestor (MRCA) was estimated for each cluster to indicate when

the RpoB S491F mutation was first acquired. The MRCAs for the clusters were similar, with

2006 (HPD 1993 – 2012) for Cluster 1, 2000 (HPD 1989 – 2008) for Cluster 2, and 2004 (HPD

2001 – 2010) for Cluster 3, suggesting the lineages emerged at similar times (Figure 3C).

Given the association of the S491F mutation in RpoB and rifamycin resistance, we

hypothesised rifamycin use might be driving the emergence of this mutation. The most

commonly used rifamycin antibiotics in clinical practice are rifampicin and rifaximin. Since

rifampicin was approved for clinical use by the United States Federal Drug Administration

(FDA) in 1971, several decades before the estimated emergence of the MRCAs, it is unlikely

to have played a major role in the emergence of the S491F mutation within this VREfm

population. However, the MRCA for all three clusters is predicted to have emerged around

the same time as the first clinical introduction of rifaximin, in 2004. The acquisition of the

same mutation in three genetically distinct lineages at a similar time, provides support for our

hypothesis that rifamycin use might be driving selection of the S491F mutation within VREfm.

Further, the structure of the three maximum clade credibility (MCC) trees (Figure 3B)

suggested the lineages have expanded over time, which may be correlated with the approval

and subsequent widespread, international use of rifaximin for the prevention of hepatic

encephalopathy since 2010 (Figure 3B).

The S491F mutation in Cluster 1 and Cluster 2 was found to be stably maintained within each

lineage after its acquisition, with few high probability events of reversion to the WT *rpoB*

allele, indicative of maintenance after emergence (Supplementary Figure 5A-B). For Cluster

3, the RpoB S491F mutation emerged a single time, with high (~0.95) posterior probability of

a single acquisition within the cluster and subsequent maintenance (Supplementary Figure

5C). There was also an equal posterior probability of either a second acquisition within the

cluster or loss of the RpoB S491F mutation within Cluster 3. Overall, the Markov jumps for all

three clusters suggests that the S491F mutation emerged and was then subsequently

maintained within these globally prevalent lineages. Taken together these data show the

S491F mutation has emerged within the VREfm population on several occasions since the

early 2000s, with the predicted dates of emergence being closely correlated with the clinical

introduction of rifaximin.

Rifaximin drives the emergence of daptomycin-resistant VREfm in a murine model of

gastrointestinal colonisation.

Rifaximin is a non-absorbable oral agent with direct antimicrobial activity in the

gastrointestinal tract. It is predominately used to prevent recurrent hepatic encephalopathy

in patients with liver cirrhosis[18,31]. Importantly, this patient cohort is high-risk for VREfm

colonisation within the gastrointestinal tract[32]. Since the Bayesian phylodynamic analyses

highlighted a putative correlation between the S491F RpoB mutation in VREfm and use of

rifaximin, we hypothesised rifaximin use may be driving the emergence of this mutation and

therefore, daptomycin-resistant VREfm within the gastrointestinal tract of patients receiving

this antibiotic. To test this hypothesis, mice were colonised with a clinical, daptomycin-

sensitive (MIC 2 mg L^{-1}) VREfm strain (Aus0233) containing a WT *rpoB* gene before being

administered a human-equivalent dose of rifaximin, rifampicin, daptomycin, or vehicle (Figure

4A and Supplementary Figure 6). Rifampicin was chosen as a comparison since it is also a

commonly used rifamycin in clinical practice. After 7 days of rifamycin treatment, we

observed rifamycin-resistant VREfm in significantly more mice receiving rifaximin (90% of

mice) or rifampicin (80% of mice) than in mice that received daptomycin (0% of mice) ($P <$

0.0001 and $P < 0.0001$; unpaired *t*-test) or vehicle (0% of mice) ($P < 0.0001$ and $P < 0.0001$;

unpaired *t*-test) (Figure 4B).

For each mouse, we then determined the percentage of individual VREfm isolates that were

rifamycin-resistant or daptomycin-resistant. There were significantly more rifamycin-

resistant VREfm isolated from mice receiving rifaximin or rifampicin than mice receiving the

vehicle control ($P < 0.001$ and $P < 0.01$; unpaired *t*-test) or daptomycin ($P < 0.001$ and $P < 0.01$;

unpaired *t*-test) (Figure 4D). Similarly, there was significantly more daptomycin-resistant

VREfm in mice receiving rifaximin or rifampicin than vehicle control ($P < 0.05$ and $P < 0.05$;

unpaired *t*-test) or daptomycin ($P < 0.05$ and $P < 0.05$; unpaired *t*-test) (Figure 4E). We

estimated that daptomycin-resistant VREfm accounted for between 0-41% of the

gastrointestinal VREfm population in mice given rifaximin and 0-36% in mice given rifampicin,

demonstrating conclusively that rifamycin administration can drive the emergence of VREfm

with cross-resistance to rifamycins and daptomycin. Notably, no daptomycin-resistant VREfm

were isolated from mice receiving daptomycin, in agreement with prior research[33].

To identify which mutations were present in the rifamycin-resistant VREfm isolates collected

from mice administrated either rifaximin or rifampicin, we randomly selected 150 isolates

from each antibiotic group (rifaximin or rifampicin, n=300 total) to undergo WGS, consisting

of 100 rifamycin-resistant isolates collected following the last day of treatment and 50 isolates

from before rifaximin or rifampicin administration. No mutations in RpoB were identified in

any VREfm isolate collected prior to rifaximin or rifampicin exposure. However, following the

administration of either rifaximin or rifampicin, VREfm carrying mutations within RpoB were

commonly identified. The S491F mutation was most abundant (n=53 and 63, respectively),

with all isolates carrying this mutation being daptomycin-resistant (Figure 4F). The H486Y

mutation was also commonly identified, albeit less so than S491F, (n=12 and 28, respectively),

with all isolates again being daptomycin-resistant. The G482D mutation was the third most

commonly identified RpoB mutation (n=15 and 6, respectively), with 13 isolates carrying this

mutation being daptomycin-resistant. Note that 2 isolates containing the G482D mutation in

the rifampicin treated mice were daptomycin-sensitive, likely due to other confounding

mutations within the genome. Other RpoB mutations in addition to S491F, H486Y, and G482D

were also identified. These included V135F, L471V, E473L, and H486A, however all VREfm

isolates carrying these mutations were daptomycin-sensitive. Importantly, the proportions of

each RpoB mutation observed in VREfm collected from the gastrointestinal tract of mice

administered either rifaximin or rifampicin, correlated closely the proportions of each

mutation observed in our collection of human clinical VREfm isolates, with the S491F

mutation most commonly identified, followed by H486Y, and then G482D, suggesting a

similar selective pressure (i.e. rifamycin use) found in our mouse experiments might be driving

the emergence of similar RpoB mutations within human clinical isolates. Taken together,

these data demonstrate that exposure to rifaximin can drive the emergence of daptomycin

resistance in colonising strains of VREfm, through the enrichment of isolates carrying select

mutations in RpoB.

VREfm collected from patients receiving rifaximin are more likely to be daptomycin-

resistant than VREfm collected from patients that did not receive rifaximin.

To further test our hypothesis that rifaximin use might be driving the emergence of

daptomycin resistance in VREfm, we performed a case-control analysis of clinical VREfm

isolates collected from a retrospective cohort of patients from a single tertiary healthcare

centre in Melbourne, Australia over 4 years. The VREfm isolates were stratified according to

whether the patient had received rifaximin within 1 month of VREfm isolate collection or not.

A total of 50 VREfm strains were identified as being from patients receiving rifaximin. As a

control group, we randomly selected 50 VREfm that had been collected from patients that

had not received rifaximin. The majority (88%) of these VREfm were screening samples. All

isolates were collected over the same time frame and from the same institution.

A maximum-likelihood phylogeny was inferred from an alignment of 12,430 core-genome

SNPs (Figure 5A). The VREfm isolates in the rifaximin and control groups were dispersed

throughout the tree, with 5 different STs (ST78, ST80, ST203, ST796, ST1421, and ST1424)

from rifaximin patients and 6 different STs (ST17, ST78, ST80, ST203, ST796, ST1421, and

ST1424) from the control patients. There were 28 VREfm from the rifaximin group that

contained a mutation within the RRDR of RpoB, with 17 containing the S491F mutation, 5

G482D, 4 H486Y, 1 E473L, and 1 G482V mutation. All isolates containing the S491F, H486Y,

and G482D mutations were resistant to daptomycin, while isolates with the E473L and G482V

mutations were daptomycin-susceptible. The control group had 2 isolates with RRDR RpoB

mutations, with 1 susceptible isolate containing a D476Y and 1 daptomycin-resistant isolate

containing the S491F substitution.

Rifaximin exposure in patients was significantly correlated with the isolation of a rifamycin-

resistant (P = 0.00007, OR = 60.0, 95% CI = 8.8 – 2562.1; Fisher's Exact Test) and daptomycin-

resistant VREfm strain (P = 0.0006, OR = 25.0, 95% CI = 5.5 – 235.3; Fisher's exact test) (Figure

5B and C). These data indicated that patients receiving rifaximin are significantly more likely

to carry rifamycin-resistant and daptomycin-resistant strains of VREfm than patients who did

not receive rifaximin, suggesting rifaximin use might be an important driver in the *de novo*

emergence and spread of daptomycin-resistant VREfm.

Discussion

In this study we have shown that specific mutations within the RRDR of RpoB represent a new,

major mechanism of daptomycin resistance in VREfm. Our analyses demonstrate these

mutations are globally distributed within the VREfm population and are as prevalent as other

well-characterised mutations within LiaRS and Cls, which have been previously associated

with daptomycin resistance in VREfm and assumed to be the dominant mechanisms[22,34,35].

Given the similar prevalence, as well as the finding that isogenic mutants carrying the G482D,

H486Y or S491F RpoB mutations display a greater level of daptomycin resistance than isogenic

strains carrying mutations in LiaRS, the RpoB mutations discovered here add to the list of

clinically relevant mutations involved in the emergence of daptomycin-resistant VREfm.

Our data suggest the S491F substitution is the dominant RRDR RpoB mutation in VREfm and

is present in at least three phylogenetically distinct lineages currently circulating within

healthcare systems globally, including in Australia, the United Kingdom, the United States of

America, and across Europe. The extent of their dissemination is likely to be underestimated

in regions with limited representation in our analyses, such as in Asia, Africa, and South

America. It is of clinical concern these lineages have successfully spread over geographic

scales and persisted for at least 15 years, since it suggests these globally prevalent lineages

might eventually compromise the therapeutic value of daptomycin for treating VREfm

infections. The Bayesian analyses provide support the S491F mutation emerged after the first

introduction of rifaximin for clinical use, for treatment of travellers' diarrhea, with each of the

MCC trees suggestive of subsequent population expansion. In 2010, rifaximin was shown to

be efficacious for the prevention of recurrent hepatic encephalopathy in patients with chronic

liver disease[18] resulting in a marked increase in its clinical use. As this patient cohort is

predisposed to gastrointestinal VREfm colonisation, we hypothesise that the use of rifaximin

in this cohort has driven the population expansion of the S491F mutation in VREfm over

subsequent years. Further, our data suggests rifampicin is not a significant driver of these

RpoB mutations since therapeutic use of rifampicin has occurred since the 1970s and the

emergence of VREfm containing these mutations is much more recent. However,

appropriately controlled clinical cohort studies will be needed to test these hypotheses.

VREfm isolates carrying the G428D, H486Y and S491F RpoB mutations were resistant to

rifamycin antimicrobials, in addition to daptomycin. Mutations within the RRDR of RpoB have

been associated with rifamycin resistance in numerous bacterial species[26], with exposure to

rifamycins being a well-documented driver in the emergence of rifamycin-resistant clones in

Staphylococcus[36–38]. In keeping with this observation, our data suggests the clinical use of

rifaximin may be responsible for selecting VREfm isolates harbouring mutations within the

RRDR of RpoB and therefore, indirectly driving the emergence of daptomycin-resistant

VREfm. Three lines of evidence support our hypothesis: (i) Bayesian phylodynamic analyses

show the emergence of phylogenetically distinct VREfm lineages carrying the S491F is

temporally linked with the clinical approval of rifaximin in the early 2000s, (ii) animal

experiments demonstrated the administration of rifaximin to mice colonised with VREfm led

to the emergence of VREfm strains within the gastrointestinal tract that carried mutations

within RRDR of RpoB and were resistant to rifamycins and daptomycin, and (iii) an analysis of

clinical VREfm isolated from humans showed patients receiving rifaximin were significantly

more likely to carry VREfm strains harbouring mutations within the RRDR of RpoB that were

resistant to both rifamycins and daptomycin, compared to patients that did not receive

rifaximin. It is therefore plausible that rifaximin exposure in this patient cohort might be an

important factor in the increasing rates of daptomycin-resistant VREfm that are currently

being reported[17,39], through the *de novo* emergence of the RpoB mutations and/or ongoing

transmission of resistant strains carrying these mutations. Appropriately controlled clinical

cohort studies are needed to dissect this hypothesis. Importantly, given the high rates of

daptomycin resistance observed, our results suggest daptomycin should not be used for

empiric therapy of invasive VREfm infections in patients who are receiving rifaximin.

Of note is our observation that rifaximin exposure in mice led to the emergence of strains

carrying similar RRDR RpoB mutations to those observed in human clinical isolates and the

relative abundance of these mutations within isolates collected from the gastrointestinal tract

of mice exposed to rifaximin closely resembled the relative abundance of these mutations in

our collection of human VREfm, with S491F, G482D and H486Y being the most abundant

mutations in both cases. These observations are suggestive of similar selective pressures,

such as rifaximin exposure, being at play in both the controlled mouse experiments of our

study and in the human population.

Overall, this research highlights the potentially serious collateral damage that can arise

following the introduction of new clinical antibiotic regimens. While the emergence of within-

family antibiotic resistance resulting from prophylactic antibiotic use has been described

previously[40,41], there are relatively few studies[37] suggesting that prophylactic antibiotics, such

as rifaximin, can lead to cross-resistance between unrelated and last-resort antibiotics, as

shown here. Careful consideration should therefore be given to the potential impact of

prophylactic antibiotics on antimicrobial stewardship practices. Current thinking[42]

recommends withholding the use of last-resort antibiotics to limit the emergence and spread

of resistance. However, our findings suggest this is not always the case, since gastrointestinal

rifaximin exposure can lead to the emergence of daptomycin-resistant VREfm in the absence

of daptomycin. Appropriate surveillance for patients colonised in the gastrointestinal tract

with nosocomial pathogens and receiving antibiotic treatment for secondary or unrelated

conditions is therefore of critical importance in limiting the emergence and spread of new

and increasingly antibiotic-resistant clones within the hospital environment.

In conclusion, we have identified a new, globally important mechanism of last-resort

antibiotic resistance in VREfm and show that prophylactic rifaximin use is a likely driver of this

resistance. These findings demonstrate the ease with which new antibiotic treatment

regiments can drive the emergence of novel multidrug resistant pathogens and highlight the

negative impact that unanticipated antibiotic cross-resistance can have on antibiotic

stewardship efforts designed to preserve the use of last-resort antibiotics. We advocate for

the judicious use of all antibiotics.

Methods

Media and reagents

E. faecium was routinely cultured at 37°C in brain heart infusion (BHI) broth (Becton Dickson)

or BHI agar (BHIA), BHI solidified with 1.5% agar (Becto Dickson). For electroporation, *E.*

faecium was cultured in BHI supplemented with 3% glycine and 200 mM sucrose (pH 7.0).

Escherichia coli was cultured in Luria broth (LB). Broth microdilution (BMD) MICs were

performed in cation-adjusted Mueller Hinton with TES broth (CAMHBT) broth (Thermo

Fisher). A concentration of 10 mg L^{-1} chloramphenicol (Sigma Aldrich) was used for plasmid

selection in *E. faecium* and *E. coli*. The following antibiotics were used at variable

concentrations for susceptibility testing: rifampicin (Sigma Aldrich), rifaximin (Sigma Aldrich),

and daptomycin (Cubicin).

Oligonucleotides were purchased from Integrated DNA Technologies and are listed in

Supplementary Table 1. Plasmids were purified with Monarch Plasmid Miniprep Kit (NEB).

PCR products and gel extractions were purified using Monarch DNA Gel Extraction Kit (NEB).

Genomic DNA was purified using the Monarch Genomic DNA Purification Kit (NEB). Phusion

and Phire DNA polymerase was purchased from New England Biolabs.

Bacterial isolates

Bacterial strains used in this study are listed in Supplementary Table 2. Australian bacterial

strains were collected across three data projects in the Microbiological Diagnostic Unit Public

Health Laboratory (MDU PHL). Two unbiased cross-sectional surveys of VREfm were

conducted between 10 November and 9 December 2015 (n=331)[43] and between 1 November

and 30 November 2018 (n=323) in the State of Victoria (referred to as the 2015 and 2018

Snapshot). During this period, all VREfm-positive isolates (including screening and clinical

samples) collected by laboratories across the state were sent to the MDU PHL. In addition,

this project included *vanA*-VREfm collected from the "Controlling Superbugs" study[20], a 15-

month (April-June 2017 and October 2017-2018) prospective study including eight hospital

sites across four hospital networks, resulting in 346 VREfm isolates (308 patients) sent for

WGS at MDU PHL. The VREfm were isolated from patient samples (including screening and

clinical samples) routinely collected from hospital inpatients. For the 'historical *vanA*-VREfm,'

every *vanA* isolate collected within MDU PHL was included. This resulted in an additional 225

isolates, sampled between 2008 and 2014.

For publicly available isolates, our aim was to capture the diversity of *E. faecium* circulating

globally by including isolates that formed part of several key studies involving hospital-

associated VREfm (as of January 2021). To be included, isolates needed to have short-read

data available, with geographic location (by country), year of collection, and source (human

or animal). Reads were only included if they had a sequencing depth of >50x. To capture the

diversity of VREfm circulating in the United States, isolates from human sources were

downloaded from the PathoSystems Resource Integration Center[44]. All isolates were

confirmed to be *E. faecium* with the Kraken2 database (v.2.1.2)[45]. The final number of

international isolates compromised those from Africa (n=8), Asia (n=25), Europe (n=2941),

North America (n=424), and South America (n=78) (Supplementary Table 2).

Antibiotic susceptibility testing

Daptomycin susceptibility testing was performed using the BMD MIC method as according to

CLSI guidelines. In a 96-well plate, a two-fold dilution series (from 32 to 0.5 mg L^{-1}) of

daptomycin was made in 100 μL volumes of CAMHBT, additionally supplemented with 50 mg

L^{-1} Ca^{2+}. An inoculum of 100 μL *E. faecium* broth culture adjusted to 1 x 10^6 CFU mL^{-1} in

CAMHBT was then added to each well. After 24 hours incubation, the MIC was defined as the

lowest antimicrobial concentration that inhibited visible growth. All assays were performed

in biological triplicate, with the median MIC reported. In accordance with recent guidelines[46],

isolates with a daptomycin MIC $\geq$ 8 mg L^{-1} were considered to be daptomycin-resistant. A

daptomycin-sensitive strain (AUS0085)[47] and a daptomycin-resistant strain (DMG1700661)[17]

were used as a control.

Rifampicin susceptibility testing was performed using the BMD method in CAMHBT. High-

level rifampicin resistance was defined with a MIC > 32 mg L^{-1}. All susceptibility testing was

performed in triplicate.

Whole-genome sequencing

Genomic DNA was extracted from a single colony using a JANUS automated workstation

(PerkinElmer) and Chemagic magnetic bead technology (PerkinElmer). Genomic DNA libraries

were prepared using the Nextera XT kit according to manufacturer's instructions (Illumina,

San Diego, CA, USA). Whole-genome sequencing was performed using Illumina NextSeq

platform, generating 150 bp paired-end reads.

The short reads of isolates sequenced at MDU-PHL are available on the NCBI Sequence Read

Archive [BioProjects PRJNA565795 (Controlling Superbugs), PRJNA433676 (2015 Snapshot)

and PRJNA856406 (2018 Snapshot), and PRJNA856406 (historical *vanA* isolates)].

Phylogenetic analysis

De novo assemblies of the genomes were constructed using Spades[48] (v3.13). In silico MLST

were determined using the program mlst with the efaecium database

(https://github.com/tseemann/mlst). The 1000 Australian genomes as well as the 4,612

Australian and international VREfm were mapped to the reference *E. faecium* genome

AUS0085 isolated from a human bacteraemia infection in Victoria, Australia (NCBI accession:

CP006620)[47] using snippy (https://github.com/tseemann/snippy) (v4.4.5), applying a minfrac

value of 10 and mincov value of 0.9. This reference was selected as it was a publicly available

complete genome collected locally and daptomycin-sensitive. A maximum likelihood

phylogenetic tree was inferred using IQ-TREE (v2.1.2) with a general time-reversible (GTR +

G4) substitution model, including invariable sites as a constant pattern and 1000 bootstrap

replicates. Recombination masking was not performed for species maximum likelihood trees

due to the small size of the resulting core alignment. All trees were mid-point rooted and

visualised in R (v4.0.3, https://www.r-project.org/) using phangorn[49] (v2.5.5), ape[50] (v5.4),

ggtree[51] (v2.3.4), and ggplot (v3.3.2).

The genome assemblies of all isolates were screened for acquired antimicrobial resistance

determinants using abriTAMR (https://github.com/MDU-PHL/abritamr).

Genome-wide association study of daptomycin resistance

A GWAS approach was applied to identify genetic variants of daptomycin resistance in *E.*

faecium. A genotype matrix of SNPs was constructed and used as input to homoplasyFinder[52]

(v0.0.0.9) to determine the consistency index at each locus and kept mutations that had an

index of ≤0.5 (indicating at least two independent acquisitions across the phylogeny). We then

ran GWAS using daptomycin resistance as a binary trait, where isolates were categorised as

resistant if their daptomycin MIC was ≥8 mg L^{-1}. To correct for population structure, we used

the factored spectrally transformed linear mixed models (FaST-LMM) implemented in

pyseer[53] (v.1.3.6), which computes a kinship matrix based on the core genome SNPs as a

random effect. The Bonferroni method was used to correct *P* values for multiple testing.

Core genome MLST (cgMLST) and clustering

cgMLST alleles for each isolate was defined using the public *E. faecium* cgMLST scheme[54] and

chewBBACA (v2.0.16), implemented locally in the COREugate pipeline (v2.0.4)

(https://github.com/kristyhoran/Coreugate). The pipeline determines the alleles of each core

gene for every isolate as defined by the specific pathogen scheme. The *E. faecium* cgMLST

scheme contains 1,423 genes. The number of allelic differences between each isolate within

this core set of genes is then determined. The cgMLST clusters were determined using single

linkage clustering and a pairwise allelic difference threshold of ≤250. This threshold was

chosen since it maximised diversity within clusters, to improve temporal sampling depth,

while still clustering based on maximum-likelihood tree structure.

Phylodynamic analyses of the emergence of the S491F RpoB mutation in VREfm lineages

To investigate the emergence of the S491F mutation in RpoB in three different lineages, as

defined with cgMLST, we undertook further analysis on these clusters/lineages. From the

species-level maximum-likelihood tree (Figure 3A), three lineages/clusters were identifiable

by cgMLST due to their size (n>50) and presence of the S491F mutation. The three clusters

were analysed independently, such that individual core-genome SNP alignments were

generated, since this increased the length of the core alignment and number of sites

considered. Snippy (https://github.com/tseemann/snippy) (v4.4.5) was used to generate the

alignments for each cluster to the corresponding reference genome (AUSMDU00004024 for

cluster 1, AUSMDU00004055 for cluster 2, and AUSMDU00004142 for cluster 3). Each core

alignment used a within 'cluster reference' (complete genome of the same cluster) to

maximise core-SNP alignment length. The reference for each cluster was chosen since they

were a locally-collected, closed genome. Recombination was removed from the final

alignment using Gubbins[55] (v.2.4.1) to ensure modelling was only informed by SNPs with tree-

like evolution within the core genome. Maximum-likelihood trees for each of the three

clusters were inferred from the core-SNP alignments [Cluster 1: (n=219 taxa) 329 SNPs;

Cluster 2: (n=85 taxa) 541 SNPs; Cluster 3: (n=68 taxa) 764 SNPs] with IQ-tree (v2.1.2)[56] with

a general time-reversible (GTR+Γ) substitution model, including invariable sites as a constant

pattern. Phylogenetic uncertainty was determined through 1000 nonparametric bootstrap

replicates.

To investigate temporal signal in the three clusters of VREfm genomes, we first used

TempEst[57] (v1.5). A root-to-tip regression analysis was performed on the root-to-tip branch

distances within the three, cluster maximum-likelihood phylogenies as a function of year of

collection, with the position of the root optimised according to the heuristic residual mean

squared method.

The frequency of the emergence of the *rpoB* mutation in VREfm was inferred using a

discrete trait model implemented in BEAST[58] (v1.10.4). Under this model the SNP alignments

are used to infer the evolutionary process (i.e. phylogenetic tree, time, and nucleotide

substitution model parameters) for the three clusters. The alignments all shared the HKY

substitution model with a gamma distribution for among-site rate variation, and a constant-

size coalescent population prior[28]. To avoid ascertainment bias due to using a SNP alignment,

the number of constant sites were taken into account for the likelihood calculations. The

molecular clock was a relaxed clock with an underlying lognormal distribution. The molecular

clock was calibrated using isolation dates for each genome by year of collection and the mean

clock rate is shared between all three alignments, but the model allows for the individual

alignments to have different standard deviations of the lognormal distribution and also

different branch rates. The mean molecular clock rate requires an explicit prior distribution,

for which we used a Γ distribution and a 0.95 quantile range of 4.9×10^{-6} and 1.1×10^{-4}

substitutions/site/year. This informative prior means that it acts as an additional source of

molecular clock calibration that can drive estimates, even in the absence of temporal signal.

The presence or absence of the S491F mutation in *rpoB* was used as a binary trait[59,60].

The trait model was shared between the three alignments, with the different Markov jumps

and rewards (ie changes of trait state and time spent in each state, respectively) recorded for

each of the three alignments. The posterior distribution of model parameters was sampled

using a Markov chain Monte Carlo of 100,000,000 iterations, sampling every 100,000

iterations. Two independent runs were run for the models. We assessed sufficient sampling

from the stationary distributions by verifying the effective sample size of key parameters was

around or above 200. The final maximum-clade credibility (MCC) trees were visualised in R

(v4.0.3, https://www.r-project.org/) using ggtree[51] (v2.3.4). The Markov jumps for the *rpoB*

trait for each alignment were visualised in R (v4.0.3, https://www.r-project.org/).

Reconstruction of clinical mutations by allelic exchange

The *liaR*^{W73C}, *liaS*^{T120A}, *rpoC*^{T634K}, *rpoB*^{G482D}, *rpoB*^{H486Y}, or *rpoB*^{S491F} mutations were recombined

into the chromosomal copy of each gene in ST796 VREfm (Ef_aus0233) by allelic exchange.

The *liaR*^{W73C} and *liaS*^{T120A} mutations were first introduced individually, then together. The

region encompassing each gene was amplified by SOE-PCR and recombined into pIMAY-Z[61]

by the seamless ligation cloning extract (SLiCE)[62] method and transformed into *Escherichia*

coli IM08B[61]. The construct was transformed into electrocompetent VREfm[62], with allelic

exchange performed as described previously[63]. Allelic exchange was performed as

described[63]. Reversion of *liaR*^{W73C} and *liaS*^{T120A}, *rpoB*^{G482D}, *rpoB*^{H486Y}, or *rpoB*^{S491F} mutations

were completed using allelic exchange with a construct containing the respective wild-type

allele. To delete the ABC transporter protein (EFAU085_02633), permease protein

(EFAU02892), or mannitol dehydrogenase (EFAU02627) from the chromosome, deletion

constructs were PCR-amplified from Ef_aus0233 genomic DNA and allelic exchange

performed as described above. Genome sequencing and analysis of all mutants was

conducted as described, with resulting reads mapped to the Ef_aus0233 reference genome

and mutations identified using Snippy (https://github.com/tseemann/snippy) (v4.4.5).

651 **VREfm *in vivo* gastrointestinal colonisation experiments**

652 Female C57BL/6 mice at 6-8 weeks of age were purchased from WEHI and maintained in a

653 specific-pathogen-free facility at the Peter Doherty Institute for Infection and Immunity. All

654 animal handling and procedures were performed in a biosafety class 2 cabinet. Animal

655 procedures were performed in compliance with the University of Melbourne guidelines and

656 approved by the University's Animal Ethics Committee

657 The dose for each antibiotic was calculated using the FDA human conversion formula to

658 ensure each mouse was given a human-equivalent dose[64]. To establish gastrointestinal

659 colonisation of VREfm, mice were administered ceftriaxone (410 mg kg^{-1} day^{-1}; AFT

660 Pharmaceuticals) via subcutaneous injection once daily for 7 days, followed by an antibiotic

661 wean period of 24 hours. Mice were then inoculated with 10^6 VREfm in 100 μl PBS by oral

662 gavage. Three days after VREfm inoculation, single-housed mice were administered either

663 rifaximin (113 mg kg^{-1} administered twice daily; Sigma Aldrich), rifampicin (123 mg kg^{-1}

664 administered once day; Sigma Aldrich), or vehicle (Corn oil with 10% DMSO) via oral gavage;

665 or daptomycin (50 mg kg^{-1} administered once daily; Cubicin) via subcutaneous injection [this

666 results in similar exposure (AUC$_{0-24}$) to that observed in humans receiving 8 mg kg^{-1} of

667 intravenous daptomycin[65]]. The above antibiotic dosing protocol was followed for 7 days.

668 Faecal samples were collected at specific time points throughout the experiment to

669 determine VREfm gut colonisation and for downstream rifamycin and daptomycin resistance

670 analysis. Faecal samples were resuspended in PBS to a normalised concentration (100 mg ml^{-}

671 ^{1}). Serial dilutions were performed, and samples were plated onto Brilliance VRE agar (Oxiod)

672 for VREfm CFU enumeration.

673 For rifamycin and daptomycin analysis, VREfm colonies (n=50 per mouse) from the Brilliance

674 VRE agar plates were replica plated onto BHIA with and without rifampicin 20 mg mL^{-1} to

determine the proportion of rifampicin-resistant VREfm in each mouse. All colonies (n=50 per

mouse) were then screened for daptomycin resistance using a daptomycin screen. Of which,

a single colony was resuspended in PBS, then diluted 1/100 into CAMHBT containing 50 mg L$^-$

^{1} Ca^{2+}, and 1/100 in MH containing 50 mg L^{-1} Ca^{2+}, and 8 mg L^{-1} daptomycin. All suspected

daptomycin-resistant colonies were confirmed using a daptomycin BMD MIC as before.

To determine which mutations were present in the rifamycin-resistant isolates, a random

selection of 300 colonies, 150 from rifaximin treated mice and 150 from rifampicin treated

mice, were sampled for WGS as described above.

Analysis of VREfm isolates from patients receiving rifaximin.

To examine the potential association of rifaximin use in humans and the presence of

daptomycin-resistant VREfm strains, we analysed VREfm collected between 2018 and 2021

from a single hospital institution in Melbourne. These isolates underwent WGS and

daptomycin and rifampicin susceptibility testing as before. Isolates were stratified according

to whether the patient received rifaximin within 1 month of VREfm isolation or remained

rifaximin free prior to isolate collection. The majority (80%) of isolates were routine screening

samples. This included 50 VREfm isolates from patients receiving or previously receiving

rifaximin at time of isolation, which were randomly matched to 50 VREfm isolates from

patients not receiving rifaximin administration. All isolates were collected within the same

time frame. The VREfm isolates were visualised in a maximum-likelihood phylogenetic tree as

before, using a core-SNP alignment of 12,430 sites. Isolate MLST was defined with the mlst

tool and mutations in RpoB were determined using Snippy

(https://github.com/tseemann/snippy) (v4.4.5) as described.

Data visualisation and statistics

All figures were generated in R (v4.0.3, https://www.r-project.org/) using tidyverse (v.1.3.1),

patchwork (v.1.1.1), and ggnewscale (v.0.4.5). Statistical analyses were performed using R

(v4.0.3, https://www.r-project.org/) and GraphPad Prism (v9.3.1) software packages. Specific

tests are given together with each result in the text.

Ethics approval

Ethical approval for analysis of patient data was received from the University of Melbourne

Human Research Ethics Committee (study number 1954615.3).

Competing Interests

The authors declare no competing interests.

Acknowledgements

This work was supported by the National Health and Medical Research Council (NHMRC) of

Australia (GNT1185213 and GNT1160745). BPH is supported by an NHMRC Investigator Grant

(GNT1196103). JCK is supported by an NHMRC Early Career Fellowship (GNT1142613). AMT

and NLS are supported by an Australian Government Research Training Program scholarship.

The Controlling Superbugs study was supported by the Melbourne Genomics Health Alliance

(funded by the State Government of Victoria, Department of Health and Human Services, and

the 10 member organizations).

Author Contributions

GPC, BPH, and CLG conceived and planned the experiments. AMT, LL, IRM, DLI, SD, and GPC

performed the planned experiments. JCK provided access to necessary patient metadata and

clinical VREfm isolates that were used in the study. JYHL, NLS, TPS, and JCK provided critical

clinical or bioinformatic insights for the study. AMT, CLG, and GPC co-wrote the manuscript

with critical feedback and input from all authors.

Corresponding Authors

Correspondence to Glen Carter or Benjamin Howden.

Data Availability

The data presented in the study are deposited under Bioprojects PRJNA565795,

PRJNA433676, PRJNA856406, and PRJNA856406.

References

1. Murray, C. J. *et al.* Global burden of bacterial antimicrobial resistance in 2019: a

systematic analysis. *The Lancet* **399**, 629–655 (2022).

2. Bylicka-Szczepanowska, E. & Korzeniewski, K. Asymptomatic Malaria Infections in the

Time of COVID-19 Pandemic: Experience from the Central African Republic. *Int. J. Environ.*

Res. Public. Health **19**, 3544 (2022).

3. Global HIV & AIDS statistics — Fact sheet. https://www.unaids.org/en/resources/fact-

sheet.

4. GBD 2019 Collaborators. Global mortality from dementia: Application of a new method

and results from the Global Burden of Disease Study 2019. *Alzheimers Dement. N. Y. N* **7**,

e12200 (2021).

5. Arias, C. A. & Murray, B. E. The rise of the *Enterococcus*: beyond vancomycin resistance.

Nat. Rev. Microbiol. **10**, 266–278 (2012).

6. Top, J., Willems, R. & Bonten, M. Emergence of CC17 *Enterococcus faecium*: from

commensal to hospital-adapted pathogen. *FEMS Immunol. Med. Microbiol.* **52**, 297–308

(2008).

7. Arthur, M. & Courvalin, P. Genetics and mechanisms of glycopeptide resistance in

enterococci. *Antimicrob. Agents Chemother.* **37**, 1563–1571 (1993).

8. Tacconelli, E. *et al.* Discovery, research, and development of new antibiotics: the WHO

priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect. Dis.* **18**, 318–

327 (2018).

9. Montero, C. I., Stock, F. & Murray, P. R. Mechanisms of Resistance to Daptomycin in

Enterococcus faecium. *Antimicrob. Agents Chemother.* (2008) doi:10.1128/AAC.00774-07.

10.   Greene, M. H. *et al.* Risk Factors and Outcomes Associated With Acquisition of

Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant *Enterococcus*. *Open*

Forum Infect. Dis. **5**, ofy185 (2018).

11.   Egli, A. *et al.* Association of daptomycin use with resistance development in

Enterococcus faecium bacteraemia—a 7-year individual and population-based analysis.

Clin. Microbiol. Infect. **23**, 118.e1-118.e7 (2017).

12.   Diaz, L. *et al.* Whole-Genome Analyses of *Enterococcus faecium* Isolates with Diverse

Daptomycin MICs. *Antimicrob. Agents Chemother.* (2014).

13.   Lellek, H. *et al.* Emergence of daptomycin non-susceptibility in colonizing

vancomycin-resistant *Enterococcus faecium* isolates during daptomycin therapy. *Int. J.*

Med. Microbiol. **305**, 902–909 (2015).

14.   Kelesidis, T., Tewhey, R. & Humphries, R. M. Evolution of high-level daptomycin

resistance in *Enterococcus faecium* during daptomycin therapy is associated with limited

mutations in the bacterial genome. *J. Antimicrob. Chemother.* **68**, 1926–1928 (2013).

15.   Werth, B. J. *et al.* Defining Daptomycin Resistance Prevention Exposures in

Vancomycin-Resistant *Enterococcus faecium* and *E. faecalis*. *Antimicrob. Agents*

Chemother. **58**, 5253–5261 (2014).

16.   Turner, A. M., Lee, J. Y. H., Gorrie, C. L., Howden, B. P. & Carter, G. P. Genomic

Insights Into Last-Line Antimicrobial Resistance in Multidrug-Resistant *Staphylococcus* and

Vancomycin-Resistant *Enterococcus*. *Front. Microbiol.* **12**, (2021).

17.   Li, L. *et al.* Daptomycin Resistance Occurs Predominantly in vanA-Type Vancomycin-

Resistant *Enterococcus faecium* in Australasia and Is Associated With Heterogeneous and

Novel Mutations. *Front. Microbiol.* **12**, 749935 (2021).

18.   Bass, N. M. *et al.* Rifaximin Treatment in Hepatic Encephalopathy. *N. Engl. J. Med.*

362, 1071–1081 (2010).

19.   Shayto, R. H., Abou Mrad, R. & Sharara, A. I. Use of rifaximin in gastrointestinal and

liver diseases. *World J. Gastroenterol.* **22**, 6638–6651 (2016).

20.   Sherry, N. L. *et al.* Pilot study of a combined genomic and epidemiologic surveillance

program for hospital-acquired multidrug-resistant pathogens across multiple hospital

networks in Australia. *Infect. Control Hosp. Epidemiol.* **42**, 573–581 (2021).

21.   Gorrie, C. L. *et al.* Key parameters for genomics-based real-time detection and

tracking of multidrug-resistant bacteria: a systematic analysis. *Lancet Microbe* **2**, e575–

e583 (2021).

22.   Miller, W. R., Bayer, A. S. & Arias, C. A. Mechanism of Action and Resistance to

Daptomycin in *Staphylococcus aureus* and Enterococci. *Cold Spring Harb. Perspect. Med.*

6, a026997 (2016).

23.   Prater, A. G. *et al.* Environment Shapes the Accessible Daptomycin Resistance

Mechanisms in *Enterococcus faecium. Antimicrob. Agents Chemother.* **63**, e00790-19.

24.   Bæk, K. T. *et al.* Stepwise Decrease in Daptomycin Susceptibility in Clinical

Staphylococcus aureus Isolates Associated with an Initial Mutation in *rpoB* and a

Compensatory Inactivation of the clpX Gene. *Antimicrob. Agents Chemother.* (2015).

25.   Cui, L. *et al.* An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and

Vancomycin in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* (2010)

doi:10.1128/AAC.00437-10.

26.   Goldstein, B. P. Resistance to rifampicin: a review. *J. Antibiot. (Tokyo)* **67**, 625–630

(2014).

27.   Rios, R. *et al.* Genomic Epidemiology of Vancomycin-Resistant *Enterococcus faecium*

(VREfm) in Latin America: Revisiting The Global VRE Population Structure. *Sci. Rep.* **10**,

5636 (2020).

28.   Duchêne, S. *et al.* Genome-scale rates of evolutionary change in bacteria. *Microb.*

Genomics **2**, e000094 (2016).

29.   Lebreton, F. *et al.* Emergence of Epidemic Multidrug-Resistant *Enterococcus faecium*

from Animal and Commensal Strains. *mBio* **4**, e00534-13.

30.   Raven, K. E. *et al.* A decade of genomic history for healthcare-associated

Enterococcus faecium in the United Kingdom and Ireland. *Genome Res.* **26**, 1388–1396

(2016).

31.   Goel, A., Rahim, U., Nguyen, L. H., Stave, C. & Nguyen, M. H. Systematic review with

meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. *Aliment.*

Pharmacol. Ther. **46**, 1029–1036 (2017).

32.   Lee, R. A. *et al.* Daptomycin-Resistant *Enterococcus* Bacteremia Is Associated With

Prior Daptomycin Use and Increased Mortality After Liver Transplantation. *Open Forum*

Infect. Dis. **9**, ofab659 (2022).

33.   Morley, V. J. *et al.* An adjunctive therapy administered with an antibiotic prevents

enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen. *eLife* **9**,

e58147 (2020).

34.   Bender, J. K. *et al.* Update on prevalence and mechanisms of resistance to linezolid,

tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature.

Drug Resist. Updat. **40**, 25–39 (2018).

35.   Tran, T. T. *et al.* Whole-Genome Analysis of a Daptomycin-Susceptible *Enterococcus*

faecium Strain and Its Daptomycin-Resistant Variant Arising during Therapy. *Antimicrob.*

Agents Chemother. **57**, 261–268 (2013).

36.   Zaw, M. T., Emran, N. A. & Lin, Z. Mutations inside rifampicin-resistance determining

region of *rpoB* gene associated with rifampicin-resistance in *Mycobacterium tuberculosis*.

J. Infect. Public Health **11**, 605–610 (2018).

37.   Lee, J. Y. H. *et al.* Global spread of three multidrug-resistant lineages of

Staphylococcus epidermidis. *Nat. Microbiol.* **3**, 1175–1185 (2018).

38.   Guérillot, R. *et al.* Convergent Evolution Driven by Rifampin Exacerbates the Global

Burden of Drug-Resistant *Staphylococcus aureus*. *mSphere* **3**, e00550-17.

39.   Albarillo, F. S., Medina, R. E., Joyce, C. S., Darji, H. & Santarossa, M. Daptomycin-

resistant VRE infections: a descriptive analysis at a single academic centre. *Infect. Dis.* **53**,

393–395 (2021).

40.   Teillant, A., Gandra, S., Barter, D., Morgan, D. J. & Laxminarayan, R. Potential burden

of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the

USA: a literature review and modelling study. *Lancet Infect. Dis.* **15**, 1429–1437 (2015).

41.   Berríos-Torres, S. I. *et al.* Activity of Commonly Used Antimicrobial Prophylaxis

Regimens against Pathogens Causing Coronary Artery Bypass Graft and Arthroplasty

Surgical Site Infections in the United States, 2006–2009. *Infect. Control Hosp. Epidemiol.*

35, 231–239 (2014).

42.   Dyar, O. J., Huttner, B., Schouten, J. & Pulcini, C. What is antimicrobial stewardship?

Clin. Microbiol. Infect. **23**, 793–798 (2017).

43.   Lee, R. S. *et al.* The changing landscape of vancomycin-resistant *Enterococcus*

faecium in Australia: a population-level genomic study. *J. Antimicrob. Chemother.* **73**,

3268–3278 (2018).

44.   Snyder, E. E. *et al.* PATRIC: The VBI PathoSystems Resource Integration Center.

Nucleic Acids Res. **35**, D401–D406 (2007).

45.   Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2.

Genome Biol. **20**, 257 (2019).

46.   Humphries, R. M. The New, New Daptomycin Breakpoint for *Enterococcus* spp. *J.*

Clin. Microbiol. **57**, e00600-19.

47.   Lam, M. M. *et al.* Comparative analysis of the complete genome of an epidemic

hospital sequence type 203 clone of vancomycin-resistant *Enterococcus faecium*. *BMC*

Genomics **14**, 595 (2013).

48.   Bankevich, A. *et al.* SPAdes: A New Genome Assembly Algorithm and Its Applications

to Single-Cell Sequencing. *J. Comput. Biol.* **19**, 455–477 (2012).

49.   Schliep, K. P. phangorn: phylogenetic analysis in R. *Bioinformatics* **27**, 592–593

(2011).

50.   Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and

evolutionary analyses in R. *Bioinformatics* **35**, 526–528 (2019).

51.   Yu, G., Smith, D. K., Zhu, H., Guan, Y. & Lam, T. T.-Y. ggtree: an r package for

visualization and annotation of phylogenetic trees with their covariates and other

associated data. *Methods Ecol. Evol.* **8**, 28–36 (2017).

52.   Crispell, J., Balaz, D. & Gordon, S. V. HomoplasyFinder: a simple tool to identify

homoplasies on a phylogeny. *Microb. Genomics* **5**, e000245 (2019).

53. Lees, J. A., Galardini, M., Bentley, S. D., Weiser, J. N. & Corander, J. pyseer: a

comprehensive tool for microbial pangenome-wide association studies. *Bioinformatics*

34, 4310–4312 (2018).

54. de Been, M. *et al.* Core Genome Multilocus Sequence Typing Scheme for High-

Resolution Typing of *Enterococcus faecium*. *J. Clin. Microbiol.* **53**, 3788–3797 (2015).

55. Croucher, N. J. *et al.* Rapid phylogenetic analysis of large samples of recombinant

bacterial whole genome sequences using Gubbins. *Nucleic Acids Res.* **43**, e15 (2015).

56. Nguyen, L.-T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: A Fast and

Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. *Mol. Biol.*

Evol. **32**, 268–274 (2015).

57. Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal

structure of heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol.*

2, vew007 (2016).

58. Suchard, M. A. *et al.* Bayesian phylogenetic and phylodynamic data integration using

BEAST 1.10. *Virus Evol.* **4**, vey016 (2018).

59. Minin, V. N. & Suchard, M. A. Counting labeled transitions in continuous-time

Markov models of evolution. *J. Math. Biol.* **56**, 391–412 (2008).

60. Minin, V. N. & Suchard, M. A. Fast, accurate and simulation-free stochastic mapping.

Philos. Trans. R. Soc. B Biol. Sci. **363**, 3985–3995 (2008).

61. Monk, I. R., Tree, J. J., Howden, B. P., Stinear, T. P. & Foster, T. J. Complete Bypass of

Restriction Systems for Major *Staphylococcus aureus* Lineages. *mBio* **6**, e00308-15.

62. Zhang, Y., Werling, U. & Edelmann, W. Seamless Ligation Cloning Extract (SLiCE)

Cloning Method. in *DNA Cloning and Assembly Methods* (eds. Valla, S. & Lale, R.) 235–244

(Humana Press, 2014). doi:10.1007/978-1-62703-764-8_16.

63.   Pidot, S. J. *et al.* Increasing tolerance of hospital *Enterococcus faecium* to handwash

alcohols. *Sci. Transl. Med.* **10**, eaar6115 (2018).

64.   Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals

and human. *J. Basic Clin. Pharm.* **7**, 27–31 (2016).

65.   Heine, H. S., Bassett, J., Miller, L., Purcell, B. K. & Byrne, W. R. Efficacy of Daptomycin

against *Bacillus anthracis* in a Murine Model of Anthrax Spore Inhalation. *Antimicrob.*

Agents Chemother. **54**, 4471–4473 (2010).

Figure 1. A. Manhattan plot of 10,530 variants, displayed by position on the reference genome and significance association with daptomycin resistance (univariate analysis using a linear mixed model). The dashed line shows the Bonferroni-corrected significance threshold. **B.** Percentage of daptomycin-resistant strains for each mutation within RpoB. The mutations within the rifampicin resistance determining region (RRDR) are shown in bold. Mutations coloured in red were associated with daptomycin resistance. The total number of strains containing each mutation is shown above each bar. **C.** Maximum-likelihood core-SNP-based phylogeny of clinical VREfm (n=1000) inferred from 6,574 SNPs, demonstrating the presence of RpoB mutations in daptomycin-resistant isolates. Overlaid are the results of *in silico* multi-locus sequence type (MLST), daptomycin phenotypic testing, and mutations associated with daptomycin resistance in RpoB. In the first circle, ST is not shown for uncommon STs (n≤5). The scale bar indicates number of nucleotide substitutions per site (top), with an approximation of SNP distance (in parentheses). **D.** Rifampicin susceptibility testing results for the WT, isogenic *rpoB* and *liaRS* isogenic mutants and complement strains (designated with -C) (n=3). **E.** Daptomycin susceptibility testing results for the WT, *rpoB* and *liaRS* isogenic mutants and complement strains (designated with -C) (n=3). The median MIC for each strain is shown.

Figure 2. A. Map of 4,476 VREfm genomes included in this study. Circle size corresponds to

total number of genomes (binned into categories), and colour corresponds to region of

isolation. Country coordinates used are the country centroid position. Map was generated in

R using ggplot2. **B.** The frequency of various RpoB mutations within the rifampicin resistance

determining region (RRDR) in 4,476 VREfm genomes, sampled from 43 MLSTs. Bars are

coloured by the number of isolates from each region of isolation containing the mutation. The

identified daptomycin resistance associated mutations are coloured in red.

A

Cluster 3

Cluster 2

Cluster 1

0.5
(~5,000 SNPs)

Region of Isolation
Africa
Asia
Australia
Europe
North America
South America
United Kingdom

Cluster
Cluster 1
Cluster 2
Cluster 3

RpoB
S491F

B

Rifaximin approval   HE

Cluster 1

1995   2000   2005   2010   2015   2020

Cluster 2

1995   2000   2005   2010   2015   2020

Cluster 3

1995   2000   2005   2010   2015   2020

C

Rifaximin approval

Cluster 1

Cluster 2

Cluster 3

1980 1985 1990 1995 2000 2005 2010 2015
Year of Emergence

Figure 3. A. Maximum-likelihood, core-SNP-based phylogeny for 4,476 VREfm inferred from

9,277 core-genome SNPs, demonstrating the presence of the S491F RpoB mutation in

international VREfm. Overlaid is the region of isolation for each strain and the presence of the

S491F mutation. The coloured branches indicate the three VREfm clusters identified with

cgMLST used as input for Bayesian evolutionary analyses. The scale bar indicates number of

nucleotide substitutions per site (top), with an approximation of SNP distance (in

parentheses). **B.** Bayesian phylodynamic analyses showing the maximum-clade credibility

(MCC) trees of the three VREfm clusters with the timing of emergence for each lineage.

Cluster 1 (n=219) was inferred from a core alignment of 1,869,554 bp containing 329 SNP

sites; Cluster 2 (n=85) was inferred from an alignment of 1,524,024 bp containing 541 SNP

sites; and Cluster 3 (n=68) was inferred from an alignment of 1,860,780 bp containing 764

SNP sites. The time in years is given on the *x* axis. The presence of the S491F RpoB trait for

each isolate is shown in purple. Overlaid onto the MCC trees is the first instance of FDA

approval for rifaximin (2004) and for hepatic encephalopathy (HE) (2010). **C.** Violin plots for

the most recent common ancestor (MCRA) for each cluster, representing when the RpoB

S491F mutation first emerged, with 95% HPD intervals. Overlaid onto violin plots is the FDA

approval date for rifaximin (2004).

Figure 4. A. Timeline of the mouse experiment. VREfm-colonised mice (n=5 for vehicle, n=10

for rifampicin, n=10 for rifaximin, n=10 for daptomycin) received a human-equivalent dose of

vehicle, rifampicin, or rifaximin (twice per day for rifaximin) for 7 days by oral gavage or

subcutaneous injection with daptomycin for 7 days. CRO=ceftriaxone; DAP=daptomycin;

RIFAX=rifaximin; RIF=rifampicin. Figure to scale. **B.** Percentage of total mice with rifampicin-

resistant VREfm strains **C.** or daptomycin-resistant VREfm strains after 7 days of antibiotic

treatment. **D.** Percentage of VREfm from each mouse (n=50 colonies per mouse) that were

resistant to rifampicin **E.** or daptomycin after 7 days of antibiotic treatment. Points represent

an individual mouse. Percentage was calculated from rifampicin or daptomycin MIC values

(either resistant or susceptible) from 50 VREfm colonies isolated from each mouse. Boxes

represent the median and interquartile range for each group. **F.** Overview of the RpoB

mutations identified in the rifampicin-resistant colonies. Each point represents a single

colony. Isolates are separated by each RpoB mutation and grouped into either daptomycin-

susceptible or daptomycin-resistant. The RpoB mutations coloured in red had an association

with daptomycin resistance. n values represent the number of isolates containing each

mutation for rifaximin and rifampicin, respectively. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$,

$****P<0.0001$; unpaired t-test (vehicle versus rifampicin or vehicle versus rifaximin and

rifampicin verses daptomycin or rifaximin verses daptomycin).

Figure 5. A. Maximum-likelihood core-SNP-based phylogeny of clinical VREfm (n=100)

inferred from 12,430 SNPs. Overlaid is the results of *in silico* MLST, rifaximin treatment group,

rifampicin phenotypic testing, daptomycin phenotypic testing, and mutations in RpoB.

Mutations associated with daptomycin resistance are bolded. The scale bar indicates number

of nucleotide substitutions per site (top), with an approximation of SNP distance (in

parentheses). **B.** Rifampicin susceptibility data for clinical VREfm (n=50 per group). Red bars

represent percent of rifampicin-resistant isolates. A Fisher's exact test comparing the

percentage of rifampicin resistance in the control versus rifaximin, $P < 0.0001$. **C.** Daptomycin

susceptibility data for clinical VREfm (n=50 per group). Red bars represent percent of

daptomycin-resistant isolates. A Fisher's exact test comparing the percentage of daptomycin

resistance in the control versus rifaximin, $P < 0.0001$.